Harnessing the Immune System to Improve Human Health

Company Overview

Overview: Inimmune designs and develops novel immunotherapeutic compounds and delivery systems that target relevant pathways of the innate immune system to drive disease-modifying responses in areas of high unmet medical need. Our lead clinical programs include a TLR4 agonist, INI-2004, for seasonal allergic rhinitis and a TLR7/8 agonist, INI-4001, for cancer delivered in proprietary liposomal formulations.

Investment Executive Summary

Company: Private, clinical stage

Current Raise: **Seeking $20M Series A Extension**

Opportunity: Looking for 3-4 investors to syndicate with a lead VC targeting a Q3 2024 close

Use of Funds: Progress two lead clinical programs to significant data readouts:

- Phase I (TLR7/8 agonist for immuno-oncology) monotherapy (data expected Q1 2025) and combination checkpoint therapy (data expected Q4 2025)
- Phase II (TLR4 agonist for allergic rhinitis) chamber study (data expected Q2 2025)

Previous Venture Funding: $22M Series A in 2020

Non-Dilutive Funding: $40M NIH funding awarded since 2016 to advance vaccine adjuvants and vaccine R&D

IP: Composition of matter patents on immunotherapies including toll-like receptor (TLR) agonists through 2038

Next Financial Event: Series B or IPO, Q1 2026 upon completion of clinical studies

2024 Accomplishments & Highlights

- Executed a license agreement & partnership with SPI Pharma for global distribution & sale of Inimmune's proprietary AS01-like and AS04-like vaccine adjuvant systems
- Completed a successful Phase I clinical trial evaluating intranasal INI-2004 for allergic rhinitis. Intranasal INI-2004 was safe & well tolerated with no drug-related serious adverse events. A dose-related improvement in nasal congestion compared to placebo was observed.
- Enrolled first patient in Phase 1 oncology clinical trial using INI-4001 (TLR7/8) monotherapy in a nanoparticle formulation.
- Awarded additional >$17M in NIH funding to continue developing our pipeline of vaccine adjuvants through 2028. These can then be added to our commercial agreement with SPI to increase revenue

Pipeline

Deep immunotherapy pipeline featuring a diverse set of innate immune modifiers for a broad array of high impact clinical indications



Disruptive Immunotherapies: Highlights of Our Lead Clinical Programs

Novel innate immune modifiers: revolutionary immunotherapies and vaccine adjuvants

Intranasal INI-2004 for Allergic Rhinitis

Mechanism: INI-2004 is a disease modifying treatment that reprograms the allergic (Th2) immune response (potentially curative).

Phase 1 (completed): SAD trial in normal healthy volunteers followed by a MAD trial with ragweed challenge in ragweed-allergic subjects.

Safety: No drug related SAEs, no MTD reached. Intranasal INI-2004 is safe and well tolerated.

Efficacy: Dose-dependent improvement in nasal congestion compared to placebo that lasted at least 16 days after final INI-2004 treatment, suggesting long-lasting disease modification.



Next step: Phase II chamber study (starts Q1 2025) to demonstrate symptomatic efficacy in moderate to severe allergic rhinitis patients after high dose ragweed exposure. Data expected Q2 2025.

INI-4001 Nanoparticle for Cancer Immunotherapy

Mechanism: Intravenous INI-4001 nanoparticle formulation that activates TLR7/8 on innate immune cells and key anti-tumor immune responses

Key pre-clinical data: INI-4001 is efficacious in tumor models as a monotherapy & combination treatment with anti-PD-1





Phase 1 (ongoing): Monotherapy dose escalation, all solid tumors until MTD reached using weekly INI-4001 administration currently ongoing. Patients that progress or achieve stable disease will transition to combination with checkpoint inhibitor. Monotherapy data expected Q1 2025.

Vaccine Adjuvant Portfolio

Mechanism: Our innate immune stimulators improve the immune response against vaccine antigens for more durable, effective & safe vaccines

Commercialization: License deal & partnership with SPI Pharma (a division of ABF) for worldwide distribution of AS01-like and AS04-like adjuvant systems. AS01 currently used in Shingrix & Arexvy with $4.3 billion of Shingrix sold in 2023. In negotiations with multiple parties for other vaccine adjuvant license agreements.